Thema: Presse: Angiogenesis inhibitor-1 in brain tumors
Presse: Angiogenesis inhibitor-1 in brain tumors
Anne[a]
04.06.2004 11:26:55
Lack of brain specific angiogenesis inhibitor-1 in brain tumors forecasts death.
"Brain specific angiogenesis inhibitor (BAI)-1 is a novel p53-inducible antiangiogenic molecule. We examined the expression of BAI-1 in glial tumors and its association with patient survival. The expression of BAI-1 was evaluated in 20 brain tumors (meningiomas, pituitary adenomas, hemangiopericytomas, hemangioblastomas), 2 normal brain samples, 5 benign gliomas, and 26 glioblastomas," scientists in South Korea report.
"In the 26 glioblastoma tumors, we also evaluated the expression of vascular endothelial growth factor (VEGF), p53, p53 mutations, and MIB-1 to determine their association with survival. BAI-1 mRNA was expressed in all benign gliomas, normal brain, and 9 out of 26 glioblastomas, but not in the other tumors," described D.H. Nam and colleagues, Sungkyunkwan University, School of Medicine.
"Low VEGF and aberrant high expression of p53 were associated with a favorable outcome in univariate survival analysis, but they were not independent factors in multivariate analysis. For the treatment response, BAI-1 expression was associated with better response to radiation therapy (p=0.014). When we divided the patients into groups according to the expression patterns of BAI-1 and VEGF mRNA, the median survival of 9 patients with high VEGF expression and no expression of BAI-1 was just 6 months, while the median survival of the other 17 patients was 14 months (p=0.013). Glioblastomas with no BAI-1 and high VEGF mRNA expression are more often associated with poor clinical outcome.
"These findings suggest that the balance between the angiogenic and antiangiogenic factors is important in the progression of glioblastoma and its response to treatment," researchers concluded.
Nam and colleagues published their study in Oncology Reports (Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep, 2004;11(4):863-869).
For additional information, contact D.H. Nam, Sungkyunkwan University, School of Medicine, Samsung Med Center, Department Neurosurgery, 50 Ilwon Dong, Seoul 135710, South Korea.
The publisher´s contact information for the journal Oncology Reports is: Professor D a Spandidos, 1, S Merkouri St., Editorial Office, Athens 116 35, Greece.
The information in this article comes under the major subject areas of Brain Cancer, Mutagenesis, Neuroscience, Oncology, and Survival & Mortality. This article was prepared by Angiogenesis Weekly editors from staff and other reports.
May 06, 2004
Copyright 2004, Angiogenesis Weekly via NewsRx.co
"Brain specific angiogenesis inhibitor (BAI)-1 is a novel p53-inducible antiangiogenic molecule. We examined the expression of BAI-1 in glial tumors and its association with patient survival. The expression of BAI-1 was evaluated in 20 brain tumors (meningiomas, pituitary adenomas, hemangiopericytomas, hemangioblastomas), 2 normal brain samples, 5 benign gliomas, and 26 glioblastomas," scientists in South Korea report.
"In the 26 glioblastoma tumors, we also evaluated the expression of vascular endothelial growth factor (VEGF), p53, p53 mutations, and MIB-1 to determine their association with survival. BAI-1 mRNA was expressed in all benign gliomas, normal brain, and 9 out of 26 glioblastomas, but not in the other tumors," described D.H. Nam and colleagues, Sungkyunkwan University, School of Medicine.
"Low VEGF and aberrant high expression of p53 were associated with a favorable outcome in univariate survival analysis, but they were not independent factors in multivariate analysis. For the treatment response, BAI-1 expression was associated with better response to radiation therapy (p=0.014). When we divided the patients into groups according to the expression patterns of BAI-1 and VEGF mRNA, the median survival of 9 patients with high VEGF expression and no expression of BAI-1 was just 6 months, while the median survival of the other 17 patients was 14 months (p=0.013). Glioblastomas with no BAI-1 and high VEGF mRNA expression are more often associated with poor clinical outcome.
"These findings suggest that the balance between the angiogenic and antiangiogenic factors is important in the progression of glioblastoma and its response to treatment," researchers concluded.
Nam and colleagues published their study in Oncology Reports (Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep, 2004;11(4):863-869).
For additional information, contact D.H. Nam, Sungkyunkwan University, School of Medicine, Samsung Med Center, Department Neurosurgery, 50 Ilwon Dong, Seoul 135710, South Korea.
The publisher´s contact information for the journal Oncology Reports is: Professor D a Spandidos, 1, S Merkouri St., Editorial Office, Athens 116 35, Greece.
The information in this article comes under the major subject areas of Brain Cancer, Mutagenesis, Neuroscience, Oncology, and Survival & Mortality. This article was prepared by Angiogenesis Weekly editors from staff and other reports.
May 06, 2004
Copyright 2004, Angiogenesis Weekly via NewsRx.co
Anne[a]
